The successful use of BTK inhibitors as therapy for CLL further demonstrates the crucial role of BCR signaling in CLL, as BTK is a crucial proximal kinase in this signaling pathway (Burger & Chiorazzi, 2013). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.